

DAFTAR PUSTAKA

- Akhmerov, A. and Marbán, E., 2020. COVID-19 and the Heart. *Circ. Res.* **126**: 1443–1455.
- Annane, D., 2021. Corticosteroids for COVID-19. *J. Intensive Med.* **1**: 14–25.
- Archived: WHO Timeline - COVID-19, 2020. 27 April 2020. (diakses 26 Agustus 2021).
- Belančić, A., Kresović, A., and Rački, V., 2020. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. *Obes. Med.* **19**: 100259.
- Bertolini, A., Peppel, I.P. van de, Bodewes, F.A.J.A., Moshage, H., Fantin, A., Farinati, F., *et al.*, 2020. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. *Hepatology* **72**: 1864–1872.
- Bhatraju, P.K., Ghassemieh, B.J., Nichols, M., Kim, R., Jerome, K.R., Nalla, *et al.*, 2020. COVID-19 in critically ill patients in the Seattle region — Case series. *N. Engl. J. Med.* **382**: 2012–2022.
- Bleyzac, N., Goutelle, S., Bourguignon, L., Tod, M., 2020. Azithromycin for COVID-19: More Than Just an Antimicrobial? *Clin. Drug Investig.* **40**: 683–686.
- Buonaguro, F.M., Puzanov, I., and Ascierto, P.A., 2020. Anti-IL6R role in treatment of COVID-19-related ARDS. *J. Transl. Med.* **18**: 9–10.
- Bwire, G.M., 2020. Coronavirus: Why Men are More Vulnerable to COVID-19 Than Women? *SN Comprehensive Clinical Medicine.* **2**: 874–876
- Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., *et al.*, 2020. COVID-19: Abnormal liver function tests. *J. Hepatol.* **73**: 566.
- Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., and Di Napoli, R., 2020. Features, Evaluation and Treatment Coronavirus (COVID-19). *StatPearls* 1–23.
- Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., *et al.*, 2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol.* **2**: e325–e331.
- Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, *et al.*, 2020a. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ.* **368** : 1-11

- Chen, Y., Zhang, K., Zhu, G., Liu, L., *et al.* 2020. Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei. *Ann. Cardiothorac. Surg.* **9**: 2118–2130.
- Gabarre, P., Dumas, G., Dupont, T., Darmon, M., Azoulay, E., and Zafrani, L., 2020. Acute kidney injury in critically ill patients with COVID-19. *Intensive Care Med.* **46**: 1339–1348.
- Hamming, I., Timens, W., Bulthuis, M., Lely, A.T., *et al.* ., 2004. Rapid Communication Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol. J Pathol* **203**: 631–637.
- Haryanto, H., Yahya, C.Q., Aritonang, R.C.A., 2020. Severe COVID-19 in the intensive care unit case series from a developing country. *J. Med Case Reports* **15** : 259
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., *et al.*, 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)* **395**: 497.
- Huttner, B.D., Catho, G., Pano-Pardo, J.R., Pulcini, C., Schouten, J., 2020. COVID-19: don't neglect antimicrobial stewardship principles! *Clin. Microbiol. Infect.* **26**: 808.
- Ikatan Dokter Indonesia, 2020. Rekomendasi IDI, Pemberian Antikoagulan Profilaksis Pada Pasien COVID-19 yang Dirawat di Rumah Sakit. *Ikat. Dr. Indones.* **4**: 57–71.
- Issa, N., Shapiro, M., 2016. Acute respiratory distress syndrome. *Trauma, Crit. Care Surg. Emergencies A Case Evidence-Based Textb.* 252–260.
- Jabłońska, K., Aballéa, S., and Toumi, M., 2021. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. *Public Health* **198**: 230–237.
- Jin, J.M., Bai, P., He, W., Wu, F., Liu, X.F., Han, *et al.*, 2020. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front. Public Heal.* **8**: 1–6.
- Kemenkes, 2019. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). *Kementrian Kesehatan Republik Indonesia.* **4**: 1–214.
- Khartabil, T.A., Russcher, H., van der Ven, A., and de Rijke, Y.B., 2020. A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. *Crit. Rev. Clin. Lab. Sci.* **57**: 415–431.

- Kollias, A., Kyriakoulis, K.G., Dimakakos, E., Poulakou, G., Stergiou, G.S., and Syrigos, K., 2020. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. *Br. J. Haematol.* **189**: 846-847
- Kopel, J., Perisetti, A., Gajendran, M., Boregowda, U., and Goyal, H., 2020. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. *Dig. Dis. Sci.* **65**: 1932–1939.
- Kumar, G., Patel, D., Herrera, M., Jefferies, D., Sakhuja, A., Meersman, M., *et al.*, 2022. Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients. *J. Med. Virol.* **94**: 372–379.
- Kuppalli, K., and Rasmussen, A.L., 2020. A glimpse into the eye of the COVID-19 cytokine storm. *EBioMedicine* 55.
- Lai, Cheng Chi, *et. al*, 2020. Clinical Manifestation extra-pulmonal. *International Antibiotic Agent* **56**: 1-4
- Ledford, H., 2020. Steroid Is First Drug Shown To Prevent Deaths From COVID-19. *Nature.* **582**:469
- Leoni, M.L.G., Lombardelli, L., Colombi, D., Bignami, E.G., Pergolotti, B., Repetti, F., *et al.*, 2021. Prediction of 28-day mortality in critically ill patients with COVID-19: Development and internal validation of a clinical prediction model. *PLoS One.* **16**: 1-13
- Lim, S., Bae, J.H., and Kwon, H.S., 2021. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat. Rev. Endocrinol.* **17**: 11–30.
- Lopes, Maria Isabela, *et. al*, 2021. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. *RMD open.* **7**: 2-8
- Maskin, L.P., Olarte, G.L., Palizas, F., Velo, A.E., Lurbet, M.F., Bonelli, I., Baredes, N.D., Rodríguez, P.O., 2020. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: A structured summary of a study protocol for a randomised controlled trial. *BMC.* **21**:1-3
- Mazzuchelli, T., Lo Priore, E., Balmelli, C., Llamas, M., Pallanza, M., Elzi, L., *et al.*, 2020. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. *J. Infect.* **81**: e148–e149.
- Medcalf, R.L., Keragala, C.B., and Myles, P.S., 2020. Fibrinolysis and COVID-19: A plasmin paradox. *J. Thromb. Haemost.* **18**: 2118-2122

- Mercuro, N.J., Yen, C.F., Shim, D.J., Maher, T.R., McCoy, C.M., Zimetbaum, P.J., *et al.*, 2020. Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or without Concomitant Azithromycin among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* E1-E5
- Moghadas, S.M., Vilches, T.N., Zhang, K., Wells, C.R., Shoukat, A., Singer, B.H., *et al.*, 2020. The impact of vaccination on COVID-19 outbreaks in the United States. *medRxiv Prepr. Serv. Heal. Sci.* 1–16.
- Nadim, M.K., Forni, L.G., Mehta, R.L., Connor, M.J., Liu, K.D., Ostermann, M., *et al.*, 2020. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat. Rev. Nephrol.* **16**:747–764.
- Newton, J.M., Aronsohn, A., and Jensen, D.M., 2015. Liver Dysfunction in Critically Ill Patients. *Diet Nutr. Crit. Care* 35–48.
- Nugroho, A., Suwarman, Nawawi, A.M., 2013. Hubungan antara Rasio Neutrofil-Limfosit dan Skor Sequential Organ Failure Assesment pada Pasien yang Dirawat di Ruang Intensive Care Unit. *J. Anestesi Perioper.* **1**: 189–196.
- Oliveira, E., Parikh, A., Lopez-Ruiz, A., Carrilo, M., Goldberg, J., Cearras, M., *et al.*, 2021. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. *PLoS One*, **16**: 1–14.
- Parasa, S., Desai, M., Thoguluva Chandrasekar, V., Patel, H.K., Kennedy, K.F., Roesch, T., *et al.*, 2020. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients with Coronavirus Disease 2019: A Systematic Review and Meta-analysis. *JAMA Netw. Open* **3**: 1–14.
- PDPI, PERKI, PAPDI, PERDATIN, IDAI., 2021. Revisi Protokol Tatalaksana COVID-19. PDPI
- PDPI, PERKI, PAPDI, PERDATIN, IDAI., 2020. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020, Pedoman Tatalaksana COVID-19.
- Periayah, M.H. *et al.*, 2017. Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis. *IJHOSCR*, **11**: 320-327
- Peta Sebaran COVID-19 | Covid19.go.id.2021.URL <https://covid19.go.id/peta-sebaran-covid19> (diakses 10.12.21).
- Pourbagheri-sigaroodi, A., 2020. Laboratory Findings in COVID-19 Diagnosis and Prognosis. *Clin. Chim. Acta*, **510**: 475-482
- Qian, Z., Lu, S., Luo, X., Chen, Y., Liu, L., 2021. Mortality and Clinical Interventions in Critically ill Patient With Coronavirus Disease 2019: A Systematic Review and

Meta-Analysis. *Front. Med.* **8**: 1031.

Ramanathan, K., Antognini, D., Combes, A., Paden, M., Zakhary, B., Ogino, M., *et al.*, 2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial, *Lancet*. **396**: 959-967

Rochwerg, B., Agarwal, A., Siemieniuk, R.A., Agoritsas, T., Lamontagne, F., Askie, *et al.*, 2020. A living WHO guideline on drugs for COVID-19. *BMJ*. **370**:1-13

Roschewski, M., Lionakis, M.S., Sharman, J.P., Roswarski, J., Goy, A., Monticelli, *et al.*, 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci. Immunol.* **5**: 1–18.

Rosendaal, F.R., 2020. Review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, *Int. J. Antimicrob. Agents* **56**: 1-25

Sakka, M., Connors, J.M., Hékimian, G., Martin-Toutain, I., Crichi, B., Colmegna, I., *et al.*, 2020. Association between D-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. *JMV-Journal Med. Vasc.* **45**: 268–274.

Shah, H., Khan, M.S.H., Dhurandhar, N. V., and Hegde, V., 2021. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. *Acta Diabetol.* **58**: 831–843.

Shen, C., Wang, Z., Zhao, F., Yang, Yang, Li, J., Yuan, *et al.*, 2020. Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. *JAMA - J. Am. Med. Assoc.* **323**: 1582–1589.

Shi, Q., Zhang, Xiaoyi, Jiang, F., Zhang, Xuanzhe, Hu, N., Bimu, C., Feng, J., Yan, S., Guan, Y., Xu, D., He, G., *et al.*, 2020. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. *Diabetes Care* **43**: 1382–1391.

Shi, Z., Puyo, C.A., 2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Ther. Clin. Risk Manag.* **16**: 1047.

Shoenfeld, Y., Gurewich, Y., Gallant, L.A., and Pinkhas, J., 1981. Prednisone-induced leukocytosis: Influence of dosage, method and duration of administration on the degree of leukocytosis. *Am. J. Med.* **71**: 773–778.

Simadibrata, D.M., and Lubis, A.M., 2020. D-dimer levels on admission and all-cause mortality risk in COVID-19 patients: a meta-analysis. *Epidemiol. Infect.* **148**: e202.

- Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.G., Dubuisson, A., Derosa, L., *et al.*, 2020. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* **182**: 1401-1418.
- Soler, M.J., Barrios, C., Oliva, R., and Batlle, D., 2008. Pharmacologic modulation of ACE2 expression. *Curr. Hypertens. Rep.* **10**: 410-414.
- Sun, F., Kou, H., Wang, S., Luo, and Y., 2020. Medication patterns and disease progression among 165 patients with coronavirus. *Arti. SSRN J.* **2019**: 10-27.
- Soni, M., Gopalakrishnan, R., Vaishya, R., Prabu, P., 2020. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. *Diabetes Metab. Syndr.* **14**: 2245.
- Sujana, K.S., Maulida, M., 2021. Efektivitas N-Acetylsistein pada Pasien COVID-19 **48**: 416-418.
- Yan, X., Li, F., Wang, X., Yan, J., Zhu, F., Tang, S., *et al.*, 2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. *J. Med. Virol.* **92**: 2573-2581.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., *et al.*, 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. *J. Intensive Care* **8**: 1-11.
- Tang, N., Li, D., Wang, X., and Sun, Z., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* **18**: 844-847.
- Tavakolpour, S., Rakhshandehroo, T., Wei, E.X., and Rashidian, M., 2020. Lymphopenia During the COVID-19 Infection: What it shows and can be learned, *Immunology Letters.* 19-21.
- Taylor, E.H., Marson, E.J., Elhadi, M., Macleod, K.D.M., Yu, Y.C., Davids, R., *et al.*, 2021. Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis. *Anaesthesia* **76**: 1224-1232.
- Terpos, E., Ntanasis-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T.N., Politou, M., *et al.*, 2020. Hematological findings and complications of COVID-19. *Am. J. Hematol.* **95**: 834-847.
- Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., *et al.*, 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J. Thromb. Haemost.* 1023-1026.

- Touret, F., Gilles, M., Barral, K., Nougairède, A., van Helden, J., Decroly, E., *et al.*, 2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci. Rep.* **10**: 1-9
- Vazzana, N., Dipaola, F., Ognibene, S., 2020. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. *Acta Clin. Belgica Int. J. Clin. Lab. Med.* **00**: 1–5.
- Vecchié, A., Batticciotto, A., Tangianu, F., Bonaventura, A., Pennella, B., Abenante, *et al.*, 2021. High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. *Intern. Emerg. Med.* 1-7
- Watson, J., Jones, H.E., Banks, J., Whiting, P., Salisbury, C., and Hamilton, W., 2019. Use of multiple inflammatory marker tests in primary care: Using Clinical Practice Research Datalink to evaluate accuracy. *Br. J. Gen. Pract.* **69**:E662-E669
- WHO, 2021. Update on COVID-19 vaccines & immune response Current global situation 1–19.
- WHO, 2021. Obesity. <https://www.who.int/health-topics/obesity>. (diakses 12.10.21).
- Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., and Prescott, H.C., 2020. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J. Am. Med. Assoc.* **2019**: 1–13.
- Xie, J., Covassin, N., Fan, Z., Singh, P., Gao, W., Li, G., Kara, T., and Somers, V.K., 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19. *Mayo Clin. Proc.* **95**: 1138–1147.
- Xu, W., Sun, N.N., Gao, H.N., Chen, Z.Y., Yang, Y., Ju, B., and Tang, L.L., 2021. Risk factors analysis of COVID-19 patients with ARDS and prediction based on machine learning. *Sci. Rep.* **11**: 1–12.
- Yan, X., Li, F., Wang, X., Yan, J., Zhu, F., Tang, S., *et al.*, 2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. *J. Med. Virol.* **92**: 2573–2581.
- Ye, Q., Wang, and B., Mao, J., 2020. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J. Infect.* **80**: 607.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., *et al.*, 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. *J. Intensive Care* **8**: 1–11.
- Zarogoulidis, P., Papanas, N., Kioumis, I., Chatzaki, E., Maltezos, E., and Zarogoulidis, K., 2012. Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. *Eur. J. Clin. Pharmacol.* **68**: 479–503.

- Zhong, Z., Li, H., Zhu, J., Ji, P., Li, B., Pang, J., Zhang, J., and Liang, X., 2021. Clinical characteristics of 2,459 severe or critically ill COVID-19 patients: A meta-analysis. *Medicine (Baltimore)*. **100**: e23781.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., *et al.*, 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**: 1054–1062.
- Zhou, P., Yang, X. Lou, Wang, X.G., Hu, B., *et al.*, 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**: 270–273.
- Zhou, Yang, and Wang, 2020. Evidence For Gastrointestinal Infection Of SARS-CoV-2 **21**: 1–9.